Medications for Rhinitis Allergic Perennial

20 results

  • Carbinoxamine maleate (carbinoxamine maleate)

    (CARBINOXAMINE MALEATE)
    Foxland Pharmaceuticals, Inc.
    Usage: Carbinoxamine maleate is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild allergic skin reactions, dermatographism, and as an adjunct therapy for anaphylactic reactions after acute symptoms have been controlled. It also helps reduce allergic reaction severity to blood or plasma.

  • Cetirizine hydrochloride (cetirizine hydrochloride)

    (Cetirizine hydrochloride)
    Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.
    Usage: Cetirizine hydrochloride oral solution is indicated for relieving symptoms of perennial allergic rhinitis and treating uncomplicated skin manifestations of chronic idiopathic urticaria in children aged 6 months to 23 months. It effectively addresses sneezing, runny nose, and hives, reducing their occurrence and severity.

  • Cetirizine hydrochloride oral solution (cetirizine hydrochloride oral solution)

    (Cetirizine Hydrochloride Oral Solution)
    APOZEAL PHARMACEUTICALS INC
    Usage: Cetirizine Hydrochloride Oral Solution is indicated for relieving symptoms of perennial allergic rhinitis in children aged 6 to 23 months, and for treating uncomplicated skin manifestations of chronic idiopathic urticaria in children aged 6 months to 5 years, reducing hives and itching.

  • Cyproheptadine hydrochloride (cyproheptadine hydrochloride)

    (CYPROHEPTADINE HYDROCHLORIDE)
    C.O. Truxton, Inc.
    Usage: This drug is indicated for perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild allergic skin reactions, amelioration of allergic blood reactions, cold urticaria, dermatographism, and as adjunctive therapy for anaphylactic reactions following standard acute treatment.

  • Cyproheptadine hydrochloride (cyproheptadine hydrochloride)

    (Cyproheptadine Hydrochloride)
    A-S Medication Solutions
    Usage: This drug is indicated for perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild allergic skin conditions like urticaria and angioedema, cold urticaria, dermatographism, and as adjunctive therapy for anaphylactic reactions following acute management.

  • Dexamethasone (dexamethasone)

    (dexamethasone)
    Amneal Pharmaceuticals NY LLC
    Usage: This drug is indicated for severe allergic conditions, dermatologic and endocrine disorders, gastrointestinal issues, hematologic disorders, certain cancers, acute nervous system conditions, ocular inflammation, renal diseases, respiratory conditions, and as adjunctive therapy for rheumatic disorders. It addresses various severe and chronic health issues unresponsive to standard treatments.

  • Fluticasone propionate (fluticasone propionate)

    (Fluticasone Propionate)
    Akorn
    Usage: Fluticasone propionate nasal spray is indicated for managing nasal symptoms of perennial nonallergic rhinitis in adults and children aged 4 years and older.

  • Ipratropium bromide (ipratropium bromide)

    (Ipratropium Bromide)
    Apotex Corp.
    Usage: Ipratropium bromide nasal solution, 0.03% is used to relieve rhinorrhea in adults and children aged 6 and older with allergic and nonallergic perennial rhinitis. It does not address nasal congestion, sneezing, or postnasal drip.

  • Levocetirizine dihydrochloride (levocetirizine dihydrochloride)

    (levocetirizine dihydrochloride)
    Proficient Rx LP
    Usage: Levocetirizine dihydrochloride tablets are indicated for relieving symptoms of perennial allergic rhinitis in children aged 6 months to 2 years and for treating uncomplicated skin manifestations of chronic idiopathic urticaria in individuals 6 months and older.

  • Levocetirizine dihydrochloride (levocetirizine dihydrochloride)

    (Levocetirizine Dihydrochloride)
    Chartwell RX, LLC
    Usage: Levocetirizine dihydrochloride oral solution is indicated for relief of perennial allergic rhinitis symptoms in children aged 6 months to 2 years, and for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months and older.